Legal Proceedings Report • Nov 28, 2022
Legal Proceedings Report
Open in ViewerOpens in native device viewer
Montpellier, November 28, 2022 - 6:00pm – MEDESIS PHARMA, a pharmaceutical biotechnology company
developing drug candidates with Aonys®, its proprietary buccal nanodroplet active ingredient administration
technology, will San Francisco, from November 29 to December 2, 2022, presenting a poster on its Phase II clinical trial drug candidate, NanoLithium® AD.
The Clinical Trials on Alzheimer's Disease (CTAD) international conference is focused exclusively on clinical trials targeting this disease. The main leaders for research into Alzheimer's disease, from the industry and academic sectors, meet up and form partnerships with a view to accelerating the development of effective treatments to fight this disease.
Professor Eugenia Maria Soto Martin, a member of Medesis Pharma's Permanent Scientific Advisory Board1, accompanied by Ms Solène Guilliot, the company's Director of Medical Affairs and Clinical
Development, will present a scientific poster setting out the design of the Phase II trial which aims to demonstr impact of NanoLithium® on behavioral and psychological symptoms in patients with mild to serious forms of Alzheimer's disease.
Medesis Pharma's NanoLithium® research program for the treatment of the psychological and behavioral disorders associated with Alzheimer's disease is currently being developed and has been prepared with Professor Jacques
Touchon (former Dean of Montpellier's School of Medicine and Chairman of the last global Alzheimer's conferences in 2019, 2020 and 2021), who is also a member of the CTAD 2022 Scientific Committee and Medesis Pharma's Permanent Scientific Advisory Board.
Since summer 2022, seven teaching hospital centers (Toulouse, Montpellier, Paris, Lille, Lyon, Marseille and Limoges)
have been opened. 10 patients have been included to date and three more are currently being integrated o 68 to be recruited. The integrations are scheduled to be completed in spring 2023. The first results on the efficacy of NanoLithium® for the treatment of the psychological and behavioral disorders associated with this disease could be
known by summer 2023 (after three months of treatment), followed by results concerning the development of t
To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB)
This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.
Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.
French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.
Medesis Pharma's shares are listed on Euronext Growth Paris: FR001844464 - ALMDP
For more information: www.medesispharma.com
MEDESIS PHARMA Tessa Olivato Tel: +33 4 67 03 03 96 [email protected]
CALYPTUS Marie Calleux Tel: +33 1 53 65 68 66 [email protected]
1 See the press release from November 21, 2022: https://www.medesispharma.com/wp-content/uploads/2022/11/CP_ScientifcAdvisoryBoard_EN.pdf
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.